Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

January 2, 2024

https://www.globenewswire.com/news-release/2024/01/02/2802671/0/en/Daxor-Corporation-Submits-Dual-510-k-CLIA-waiver-Application-to-the-FDA-for-Its-Advanced-Next-Generation-Blood-Volume-Analyzer.html

The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the Bedside

Oak Ridge, TN, Jan. 02, 2024 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq:DXR), the global leader in blood volume measurement technology, today announces it has submitted its next-generation blood volume analyzer – Daxor BVA – to the U.S. Food and Drug Administration (FDA) via the 510(k)/CLIA-waiver dual submission pathway. Potential clearance is expected during the first half of 2024. The Company’s mission is to advance healthcare by enabling optimal fluid management.

Read more at globenewswire.com

Related news for (DXR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.